Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 3

Efficacy, Safety, and Pharmacokinetics of Femoral Nerve Block With EXPAREL in Total Knee Arthroplasty

NCT02713178 · View on ClinicalTrials.gov ↗

Study Summary

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study in 232 adult subjects undergoing primary unilateral TKA under general or spinal anesthesia.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG bupivacaine liposome injectable suspension

Study Locations (17)

Pennsylvania

  • Indiana Regional Medical Center — Indiana
  • Thomas Jefferson University Hospital — Philadelphia
  • Chan Soon-Shiong Medical Center — Windber

Other

  • Ziekenhuis Oost-Limburg — Genk
  • Aarhus University Hospital — Aarhus C
  • Regionshospital Silkeborg — Silkeborg

Florida

  • Jackson Memorial Hospital/University of Miami — Miami
  • Pensacola Research Associates — Pensacola

Massachusetts

  • Brigham and Women's Hospital — Boston
  • Massachusetts General Hospital — Boston

Texas

  • Hermann Drive Surgical Hospital — Houston
  • Westside Surgical Hospital — Houston

Alabama

  • Horizon Research Group, Inc — Mobile

Colorado

  • Denver Metro Orthopedics — Englewood

New York

  • Montefiore Medical Center — The Bronx

Trial Details

FieldValue
Enrollment Target 232 participants
Start Date 2016-06-03
Est. Completion 2017-06-30
Phase Phase 3

Sponsor

Pacira Pharmaceuticals

31 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02713178

The ClinicalTrials.gov registry entry for NCT02713178 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 232 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pacira Pharmaceuticals, which has 31 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Pain appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT02713178 reports 17 study locations spanning 10 distinct geographic areas — top geographies include Pennsylvania, Other, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT02713178 about?

NCT02713178 is a clinical study titled "Efficacy, Safety, and Pharmacokinetics of Femoral Nerve Block With EXPAREL in Total Knee Arthroplasty". This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study in 232 adult subjects undergoing primary unilateral TKA under general or spinal anesthesia.

What is the current status of trial NCT02713178?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 232 participants. The study started on 2016-06-03. Estimated completion is 2017-06-30.

What conditions does trial NCT02713178 study?

This clinical trial studies the following conditions: Pain. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT02713178?

The interventions under investigation include: Placebo (DRUG), bupivacaine liposome injectable suspension (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT02713178?

This trial is sponsored by Pacira Pharmaceuticals, which has 31 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT02713178 being conducted?

This trial has 17 study locations across Alabama, Colorado, Florida, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial